#USA #Woburn, Massachusetts #Sirtex Medical #SIR-Spheres #DOORwaY90

Sirtex Medical Achieves Groundbreaking Results in DOORwaY90 Study

Recently, the DOORwaY90 study conducted by Sirtex Medical has reported astounding results concerning local tumor control in patients suffering from unresectable hepatocellular carcinoma (HCC). This pivotal, multicenter trial showcased a remarkable 100% local tumor control rate using SIR-Spheres®, a radiotherapy technique that utilizes selective internal radiation therapy (SIRT) with Yttrium-90 (Y-90). The study aimed to evaluate the effectiveness and safety of these microbeads in providing powerful tumor responses without compromising liver functionality.

Key Outcomes of the Study

One of the critical objectives of the DOORwaY90 study was to achieve defined primary endpoints that would demonstrate the efficacy of SIR-Spheres. Impressively, the study achieved a global response rate (GRR) of 99%, with a complete response rate (CR) of 90%. These outcomes were validated through a blinded, independent central review, illustrating the reliable nature of the findings. Furthermore, every evaluable patient displayed positive responses to the treatment, which is among the highest reported rates for Y-90 therapy, reflecting the innovative approach to targeting tumors effectively.

Patients who participated in the study experienced not only durable responses, but an astonishing 75% had responses lasting over six months. The mean duration of these responses was around 295 days, underscoring the potential of SIR-Spheres to deliver sustained tumor responses while preserving critical liver function. Encourageably, over 95% of the patients maintained stable liver functions one year post-treatment, showcasing the meticulous nature of personalized dosimetry

The Significance of Personalized Dosimetry

Dr. Armeen Mahvash, an interventional radiologist at MD Anderson Cancer Center and a principal investigator of the DOORwaY90 study, emphasized the importance of customized dosimetry in achieving consistent patient responses. She stated, “The high rates of complete response, durability, and preservation of liver function observed in this study provide physicians greater confidence in using radioembolization as a definitive treatment option directed at the liver.” This statement highlights how tailoring treatment approaches can enhance patient care without sacrificing overall health.

According to Matt Schmidt, CEO of Sirtex Medical, these results significantly raise the standards for expected outcomes with Y-90 therapy. He mentioned that a global response rate of 99% and a local tumor control rate of 100% underscore the capabilities of personalized dosimetry with SIR-Spheres, positioning it as a superior alternative to conventional HCC treatments.

About SIR-Spheres®

SIR-Spheres® Y-90 is the only FDA-approved therapy for radioembolization targeting both metastatic colorectal cancer (mCRC) in the liver and unresectable HCC. These microbeads function by delivering targeted radiation to the tumor while sparing surrounding healthy liver tissue. Additionally, they are indicated for patients with compensated liver function and Child-Pugh Class A cirrhosis, showcasing the versatility and safety of the treatment.

As with any medical procedure, there are risks involved with the use of SIR-Spheres. Common side effects may include abdominal pain, nausea, and constipation, alongside more comprehensive risks outlined on the company's website.

The Future of Cancer Treatment

As the healthcare landscape continues to evolve, the implications of this groundbreaking study by Sirtex Medical represent a significant leap forward in cancer treatment strategies. The tailored approach showcased in the DOORwaY90 study not only illustrates the capability of modern oncology to deliver effective quality care but also signifies hope for patients diagnosed with HCC and similar malignancies.

For those interested in learning more about SIR-Spheres or looking for guidance on incorporating personalized dosimetry into clinical practice, Sirtex encourages reaching out via their dedicated communication channels.

For further information about cutting-edge interventional oncology solutions offered by Sirtex Medical, visit www.sirtex.com or contact them directly to explore innovative avenues in cancer care.